BCAX
Bicara Therapeutics Inc. Common Stock- Healthcare
- Biotechnology
- $1.13B market cap
Forecast run · Oct 29, 2026Upside rank 126 of 3,186
Model Signal
ForecastQ Daily Probabilities
61.2%
28.1%
62.1%
Analyst Consensus
Recommendation2.33/5 Buy
Last price$17.07
Price target$32.86
Implied move+92.5%
Analysts9
ForecastQ Portfolios
BCAX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.